Market Trends– category –
-
CGT Manufacturers Transform Regulatory Demands into Innovation Drivers: New Strategies for Enhanced Quality and Efficiency
MasterControl USA Overview Cell and gene therapy (CGT) manufacturers are adopting new strategies to leverage stringent regulatory requirements as opportunities for innovation and quality improvement, rather than mere obstacles. Central t... -
CDMO Capacity Crunch Persists in Cell and Gene Therapy Sector: Strategic Partnerships Crucial for Accelerating Innovation
Contract Pharma USA Overview The cell and gene therapy (CGT) sector faces a severe and persistent capacity crunch among Contract Development and Manufacturing Organizations (CDMOs), driven by soaring demand. This bottleneck significantly... -
Autolus Therapeutics Reports 119% YoY Increase in Q2 2026 AUCATZYL® Net Product Sales to $45.7M, Raising Full-Year Guidance and Securing $250M Credit Facility for Extended Runway
Autolus Therapeutics, Inc. (Press Release via GlobeNewswire) USA Overview Autolus Therapeutics announced that its CAR T-cell therapy, AUCATZYL® (obecabtagene autoleucel; obe-cel), generated $45.7 million in net product sales for Q2 2026,... -
Reprogramming the Future: Liv Hospital Details iPSC Therapy’s Transformative Role in Regenerative Medicine
Liv Hospital Turkey Overview Liv Hospital recently published an insightful article on induced pluripotent stem cell (iPSC) therapy, highlighting its profound impact on regenerative medicine, diverse applications, and global clinical prog... -
CRISPR’s Clinical Horizon: Liv Hospital Report Maps 2026 FDA Landscape and Broad Therapeutic Potential
Liv Hospital Turkey Overview Liv Hospital has published a comprehensive review outlining the latest advancements in CRISPR gene-editing technology, emphasizing its revolutionary impact on medical treatments. The report highlights breakth... -
FDA Advances AI Medical Device Regulation Clarity Amidst “AI Premium” Driving Investment, Challenges Remain for Generative AI
Facebook (STAT News) USA Overview The MedTech industry experienced a strategic reset, with AI-enabled companies commanding a 19% premium on average deal size in 2025, and US startups raising $14.2 billion. While the FDA is updating guida... -
UBS and FactSet Invest in Finster AI, HSBC in Model ML, Accelerating AI Adoption in Finance
TechCrunch USA Overview UBS Investment Bank and FactSet have invested in Finster AI, an AI intelligence platform, signaling interest in technologies that support the evolution of investment banking workflows. HSBC Asset Management also i... -
Situational Awareness Invests Additional $400 Million in Chip Startup Source Foundry, Bringing Total to $500 Million
CryptoRank USA Overview AI-focused hedge fund Situational Awareness has invested an additional $400 million into Source Foundry, a chip manufacturing startup, bringing its total investment to $500 million. This significant investment sig... -
FriskAI Emerges from Stealth with $3.6 Million Pre-Seed Funding for AI Agent Runtime Monitoring Platform
Dealroom.co Unknown Overview FriskAI emerged from stealth with $3.6 million in pre-seed funding to develop a platform that monitors AI agents in production, specifically targeting regulated industries like healthcare, insurance, and fina... -
U.S. Health Insurers Offer AI Reality Check: Oscar Health Emphasizes Single Platform Advantage, Centene Demands Tangible Benefits
Endpoints News USA Overview U.S. health insurers are offering a pragmatic perspective on their AI strategies amidst billions of dollars in investments by major players like UnitedHealth Group and CVS Health. Oscar Health highlights its u...
